|
Prevention
| Integrative Medicine
>
Aspirin
/ Vitamin
E
|
|
JAMA,
2005;294:105-106; Vol.
294 No. 1, July 6, 2005
|
|
|
|
|
Abstract |
|
|
|
Low-Dose
Aspirin and Vitamin E
Challenges
and Opportunities in Cancer Prevention
Eric
J. Jacobs, PhD; Michael J. Thun, MD
Epidemiology and Surveillance Research,
American Cancer Society, Atlanta, Ga.
|
|
|
|
|
First 150 words of the full text.
This issue of JAMA includes 2
articles from the Women’s Health Study (WHS).1-2
This 10-year long, placebo-controlled, randomized trial of
low-dose aspirin and vitamin E included nearly 40 000
predominantly middle-aged women with no history of cancer
or cardiovascular disease.3
The WHS used a 2 x 2 factorial design to evaluate
the effects of low-dose aspirin (100 mg) taken every other
day and 600 IU of vitamin E (in the form of natural-source -tocopherol),
also taken every other day.
Neither alternate-day, low-dose aspirin nor vitamin E showed any
evidence of efficacy in reducing overall cancer incidence or
mortality.1-2
With respect to noncancer outcomes, notable findings for
low-dose aspirin included a reduction in stroke risk, no
apparent effect on myocardial infarction, and an increased risk
of gastrointestinal bleeding requiring transfusion.4
Vitamin E had no apparent effect . . . [Full
Text of this Article]
|
|
|
|
|
© 2005 American Medical Association.
All Rights Reserved.
|
|
|
Extract
|
Full
Text |
Reprint
|
|
|
|